Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 2Neuroblastoma 2Wilms Tumor 1Sarcoma, Ewing 1Retinoblastoma 1Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 353-Iodobenzylguanidine 34Peripheral Blood Stem Cell Transplantation 31dinutuximab 30Granulocyte Colony-Stimulating Factor 30Radiotherapy 29sargramostim 28Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16naxitamab 15Ifosfamide 15Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroblastoma × racotumomab × Clear all
NCT02998983 2023-09-11

Racotumomab in Patients With High-risk Neuroblastoma

Laboratorio Elea Phoenix S.A.

Phase 2 Completed
39 enrolled
CNS

Neuroblastoma

NCT01598454 2015-07-29

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Laboratorio Elea Phoenix S.A.

Phase 1 Completed
15 enrolled
CNSGenitourinaryOther solid neoplasmSarcoma

Glioma, Wilms Tumor, Neuroblastoma, Retinoblastoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡